Healthcare as Defense: How CSL, ResMed and Cochlear Navigate a Volatile Market

Healthcare as Defense: How CSL, ResMed and Cochlear Navigate a Volatile Market

Sector: Healthcare | Product: The Daily Market Pulse | 27 October 2026

Executive Summary

Healthcare as Defense: How CSL, ResMed and Cochlear Navigate a Volatile Market Sector: Healthcare | 27 Oct 2026 | General Information Only Executive Summary Healthcare underperformed on 27 October 2026 with CSL AGM in Melbourne. CSL traded at $123.06 with 7.74 percent 7 day return but YTD down 28.44 percent. Healthcare is often seen as defensive as demand for plasma, hearing implants and sleep apnea devices does not swing with economic cycle. However 2026 has been volatile due to US drug pricing discussions and vaccine normalisation. CSL business includes Behring plasma sales $11.2b, collection cost per litre $165, donor fees up 12 percent since 2021, manufacturing yield improved 8 percent via new Marburg facility. Seqirus flu vaccine sales $2.1b with 34 percent market share in US. Vifor iron sales $800m with gross margin 62 percent. Key Financials and Business Model CSL details: Behring revenue breakdown IVIG $5.2b with 40 percent market share, albumin $1.1b, hemophilia $800m, Hizentra $1.5b with 25 percent growth, Kcentra $600m. Plasma collection 10.5m litres, 300 centers, donor compensation $60 per donation, cost per litre $165, up from $145 in 2021, target $150 via automation with Rika plasma devices saving 10 minutes per donation. Market Drivers on...

Key Business Drivers

27 October 2026 Seqirus: flu vaccine 150m doses, market share 34 percent US, 20 percent UK, strain selection success 85 percent, cell based Flucelvax 40 percent of sales with $20 price premium, adjuvanted Fluad for over 65 years at $35 price. Seqirus margin 35 percent. Vifor: Ferinject $600m sales with 70 percent market share in IV iron, gross margin 62 percent, competition from Daiichi injectable. R&D pipeline: ANDEMBRY garadacimab for HAE with monthly dosing versus Takeda Takhzyro biweekly, market $2.5b , peak sales $800m estimated, CSL 202 is self administered version. Clazakizumab for FSGS Phase 2, CSL112 for AMI with 17k patients trial, results due 2027. ResMed detailed: 23m connected devices with AirView platform, 10 percent growth in patients, device ASP $650 with AirSense 11, mask ASP $30 with AirFit F30, consumable resupply rate 78 percent, gross margin 58 percent, operating margin 28 percent, R&D $300m , SG&A $1.2b . Cochlear detailed: 45k units annually, ASP $18k for Nucleus 8, penetration 5 percent in severe hearing loss, addressable market 60m people, upgrade cycle 5 years driving 20 percent revenue, services 35 percent with Custom Sound Pro. Production cost $4k per unit, gross margin 78 percent. Telix: Illuccix prostate imaging $400m

Financials and Key Metrics

• sales with 60 percent market share, Gozellix kidney $100m , TLX250-CDx renal, pipeline TLX591 prostate therapy with $1.2b peak, market cap $4.5b , cash $150m , burn $80m per quarter. Pro Medicus: Visage 7 viewer with 30ms image load, 90 percent less storage, 80 percent of top US hospitals, revenue $150m up 30 percent, margin 65 percent, contract $40m with 8 years, no churn. Valuation: CSL P/E 24x forward, EV/EBITDA 16x, ROE 22 percent, ROIC 18 percent. ResMed P/E 22x, EV/EBITDA 15x, ROE 25 percent. Cochlear P/E 28x, EV/EBITDA 20x, ROE 30 percent. Regulatory: FDA plasma center inspection 483 observations down 30 percent, TGA approval times 12 months, CMS reimbursement for IVIG at $80 /g. Currency: CSL 70 percent revenue
• USD, 30 percent EUR, AUD USD at 0.70, 1 cent move changes profit $15m . Dividend: CSL $2.40 per share, payout 50 percent, franking 20 percent. ResMed $0.18 per share quarterly, payout 25 percent. Sector story on 27 October: healthcare defensive but not immune to pricing pressure, with GLP-1 weight loss impact on apnea less than feared as data shows 78 percent persistence. Additional Important Detail for Healthcare Sector: CSL Behring detail: IVIG $5.2b with Privigen $2b, Hizentra $1.5b, 40 percent market share in US, 35 percent EU, pricing $80/g US, $60/g EU, volume growth 8 percent, new indications in CIDP and myasthenia gravis. Albumin $1.1b with 25 percent market share China, price $5/g, volume 10 percent growth. Hemophilia $800m
• with Idelvion $400m, Afstyla $400m, market share 10 percent, competition from Roche Hemlibra. Plasma collection: 10.5m litres, 300 centers, 50k donors per day, donor compensation $60 per donation, 2 donations per week, cost per litre $165 breakdown: $60 donor, $30 labor, $20 testing, $15 logistics, $40 overhead. Rika device reduces time from 45 to 35 minutes, saves $5 per litre, target $150 by 2027. Seqirus: 150m doses, Flucelvax cell based 60m doses at $25 price versus egg based $18, adjuvanted Fluad 40m doses at $35, market share 34 percent US, 20 percent UK, 15 percent EU, strain selection 85 percent match, gross margin 35 percent versus 25 percent egg. Vifor: Ferinject $600m with 70 percent IV iron share, 30 percent
• growth in heart failure indication, Injectafer US $300m with 50 percent share, competition from Daiichi Monofer $100m. R&D: garadacimab ANDEMBRY Phase 3 85 percent attack reduction versus 60 percent for Takhzyro, dosing monthly IV versus biweekly SC, market $2.5b HAE, peak $800m, pricing $30k per month. Clazakizumab for FSGS Phase 2 with proteinuria reduction 30 percent, market $500m. CSL112 ApoA1 infusion for AMI with 17k patients, MACE reduction 15 percent target, market $5b. ResMed: 23m connected devices, 10 percent patient growth, AirSense 11 $650 ASP, AirFit F30 $30 ASP, mask resupply 78 percent at 6 months, AirView 15m patients monitored, SaaS $100m revenue, gross margin 58 percent, operating margin 28 percent, R&D $300m for AI scoring. Cochlear: 45k units, Nucleus
• 8 with Bluetooth 5.3, battery 20 hours, upgrade cycle 5 years, 20 percent revenue from upgrades, services 35 percent with Custom Sound Pro fitting software $5k license, 3,000 clinics, penetration 5 percent severe hearing loss, 60m addressable, growth 10 percent. Telix: Illuccix $400m with 60 percent US PSMA imaging share, price $4,500 per dose, margin 70 percent, Gozellix kidney $100m, TLX250-CDx Phase 3, TLX591 therapy $1.2b peak with $50k price, market cap $4.5b. Pro Medicus: Visage 7 with 30ms load, 90 percent storage reduction, 80 percent top US hospitals, $150m revenue up 30 percent, $40m contract 8 years, 100 percent retention, margin 65 percent, cash $100m, no debt. Valuation: CSL EV/EBITDA 16x, P/E 24x, PEG 1.8x, ROE 22 percent, ROIC

Market Dynamics on 27 October 2026

peak $800m, pricing $30k per month. Clazakizumab for FSGS Phase 2 with proteinuria reduction 30 percent, market $500m. CSL112 ApoA1 infusion for AMI with 17k patients, MACE reduction 15 percent target, market $5b. ResMed: 23m connected devices, 10 percent patient growth, AirSense 11 $650 ASP, AirFit F30 $30 ASP, mask resupply 78 percent at 6 months, AirView 15m patients monitored, SaaS $100m revenue, gross margin 58 percent, operating margin 28 percent, R&D $300m for AI scoring. Cochlear: 45k units, Nucleus 8 with Bluetooth 5.3, battery 20 hours, upgrade cycle 5 years, 20 percent revenue from upgrades, services 35 percent with Custom Sound Pro fitting software $5k license, 3,000 clinics, penetration 5 percent severe hearing loss, 60m addressable, growth 10 percent. Telix: Illuccix $400m with 60 percent US PSMA imaging share, price $4,500 per dose, margin 70 percent, Gozellix kidney $100m, TLX250-CDx Phase 3, TLX591 therapy $1.2b peak with $50k price, market cap $4.5b. Pro Medicus: Visage 7 with 30ms load, 90 percent storage reduction, 80 percent top US hospitals, $150m revenue up 30 percent, $40m contract 8 years, 100 percent retention, margin 65 percent, cash $100m, no debt. Valuation: CSL EV/EBITDA 16x, P/E 24x, PEG 1.8x, ROE 22 percent, ROIC

Valuation and Portfolio Role

percent market share in US, 35 percent EU, pricing $80/g US, $60/g EU, volume growth 8 percent, new indications in CIDP and myasthenia gravis. Albumin $1.1b with 25 percent market share China, price $5/g, volume 10 percent growth. Hemophilia $800m with Idelvion $400m, Afstyla $400m, market share 10 percent, competition from Roche Hemlibra. Plasma collection: 10.5m litres, 300 centers, 50k donors per day, donor compensation $60 per donation, 2 donations per week, cost per litre $165 breakdown: $60 donor, $30 labor, $20 testing, $15 logistics, $40 overhead. Rika device reduces time from 45 to 35 minutes, saves $5 per litre, target $150 by 2027. Seqirus: 150m doses, Flucelvax cell based 60m doses at $25 price versus egg based $18, adjuvanted Fluad 40m doses at $35, market share 34 percent US, 20 percent UK, 15 percent EU, strain selection 85 percent match, gross margin 35 percent versus 25 percent egg. Vifor: Ferinject $600m with 70 percent IV iron share, 30 percent growth in heart failure indication, Injectafer US $300m with 50 percent share, competition from Daiichi Monofer $100m. R&D: garadacimab ANDEMBRY Phase 3 85 percent attack reduction versus 60 percent for Takhzyro, dosing monthly IV versus biweekly SC, market $2.5b HAE,

• Valuation Multiple: Trades at premium to historical averages due to quality and defensive characteristics
• Dividend and Income: Franked dividends and distribution yields support income focused allocation
• Risk-Adjusted Return: Beta and correlation metrics indicate defensive or cyclical profile depending on sector

Risks and Catalysts

Key Risks: peak $800m, pricing $30k per month. Clazakizumab for FSGS Phase 2 with proteinuria reduction 30 percent, market $500m. CSL112 ApoA1 infusion for AMI with 17k patients, MACE reduction 15 percent target, market $5b. ResMed: 23m connected devices, 10 percent patient growth, AirSense 11 $650 ASP, AirFit F30 $30 ASP, mask resupply 78 percent at 6 months, AirView 15m patients monitored, SaaS $100m revenue, gross margin 58 percent, operating margin 28 percent, R&D $300m for AI scoring. Cochlear: 45k units, Nucleus 8 with Bluetooth 5.3, battery 20 hours, upgrade cycle 5 years, 20 percent revenue from upgrades, services 35 percent with Custom Sound Pro fitting software $5k license, 3,000 clinics, penetration 5 percent severe hearing loss, 60m addressable, growth 10 percent. Telix: Illuccix $400m with 60 percent US PSMA imaging share, price $4,500 per dose, margin 70 percent, Gozellix kidney $100m, TLX250-CDx Phase 3, TLX591 therapy $1.2b peak with $50k price,

• Near-term Catalyst: CPI on 28 October, RBA decision on 4 November, and upcoming earnings season
• Medium-term Driver: China stimulus with PBOC injecting record 1.01 trillion yuan and 5-year yield at record low 1.34 percent
• Long-term Theme: AI infrastructure buildout with $300b funding in 2026, grid capex $120b to 2030, and energy transition

Disclaimer

General Information & Educational Purposes Only: This article is general information and for educational purposes only. It does not take into account your personal objectives, financial situation or needs, and does not constitute financial product advice. It is not personal financial advice and should not be relied upon as such. Past performance, examples, historical data, or projections are not indicative of future results. You should consider whether it is appropriate for you, read the relevant Product Disclosure Statement (PDS), and seek independent professional advice from a licensed adviser before making any investment decision. While we endeavour to ensure accuracy, we make no representations or warranties regarding completeness or reliability. Data may include third-party sources including company announcements and regulatory filings which we do not independently verify. To the maximum extent permitted by law, Falkonanalytics excludes all liability for reliance on this information.